Purpose

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center (pediatric and adult) and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: - To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. - To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and adult patients from participating sites. Design: - This is a multicenter tissue procurement protocol with NCI as the coordinating center. - For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. - For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. - Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. - This study has three separate consent forms: one for adult patients at the NIH Clinical Center to opt to donate their samples for ongoing research on assay development and studies of molecular pathways; and two for the generation of preclinical models (adult and pediatric). Adult patients at the NIH and participating sites, and also pediatric patients (NIH Clinical Center only), can opt to donate samples to create preclinical models to study tumor biology and genetics, and to develop new therapies for cancer. - Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.

Conditions

Eligibility

Eligible Ages
Under 110 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ADULT:
  • Patients 18 years of age and older who are being evaluated and/or treated for cancer at the NIH Clinical Center or at participating sites:
  • Who have a newly diagnosed solid tumor, lymphoma or multiple myeloma malignancy for which they have not yet received treatment, or
  • Who have a previously treated solid tumor, lymphoma or multiple myeloma malignancy that is now recurrent or currently progressing on treatment indicated by:
  • Radiographic evidence of tumor growth and/or new metastases, or
  • documented evidence by the treating physician of signs/symptoms of clinical disease progression, or
  • Who are currently undergoing treatment (adjuvant, neoadjuvant, etc.), are within the first two (2) cycles of treatment, and for whom disease response has not yet been assessed
  • --In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle.
  • For matched pair collections only (tissue + blood), patients with ongoing partial response (PR) or stable disease (SD) are eligible.
  • Confirmation of viable malignancy and/or <90% tumor necrosis must be confirmed to the coordinating site, as indicated in the final pathology report, for patients enrolled with PR or SD.
  • ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol.

Exclusion Criteria

  • ADULT:
  • Patients with invasive fungal infections
  • Patients with active and/or uncontrolled infections or who are still recovering from an infection:
  • Actively febrile patients with uncertain etiology of febrile episode
  • All antibiotics should be completed at least 1 week (7 days) prior to collection
  • No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
  • Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion.
  • Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV. Testing for hepatitis B or other infections for eligibility will be performed only if clinically indicated.
  • Patients with Hepatitis A as indicated by anti-HAV IgM reactivity
  • -Note: Patients that are anti-HAV IgG reactive only are not excluded
  • Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.
  • -Documentation of clinical progression by the assessing physician would be acceptable if imaging demonstrating progressive disease has not been obtained.
  • Blood only collections from patients with partial or stable disease response:
  • Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing (i.e., prolonged) stable disease given the poor rate of model generation from such samples.
  • Blood will not be collected from patients between doses within a single treatment cycle.

INCLUSION CRITERIA - PEDIATRIC:

- Patients younger than 18 years of age with a histologically or cytologically confirmed diagnosis of cancer (solid tumor, lymphoma or multiple myeloma) who are being treated for cancer at the NIH Clinical Center and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue collected.

- Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or blood/biological fluid samples used for research as outlined in this protocol, or, consent from a parent/guardian with assent from the child.

EXCLUSION CRITERIA - PEDIATRIC:

- Patients with invasive fungal infections

- Patients with active and/or uncontrolled infections or who are still recovering from an infection:

- Actively febrile patients with uncertain etiology of febrile episode

- All antibiotics should be completed at least 1 week (7 days) prior to collection

- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics

- Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion.

- Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV. Testing for hepatitis B or other infections for eligibility will be performed only if clinically indicated.

- Patients with Hepatitis A as indicated by anti-HAV IgM reactivity

--Note: Patients that are anti-HAV IgG reactive only are not excluded

- Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.

--Documentation of clinical progression by the assessing physician would be acceptable if imaging demonstrating progressive disease has not been obtained.

- Blood only collections from patients with partial or stable disease response:

--Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing (i.e., prolonged) stable disease given the poor rate of model generation from such samples.

- Blood will not be collected from patients between doses within a single treatment cycle.

Study Design

Phase
Phase 1
Study Type
Interventional
Intervention Model
Single Group Assignment
Primary Purpose
Other
Masking
None (Open Label)

Recruiting Locations

Vanderbilt University
Nashville, Tennessee 37232
Contact:
Jennifer Pietenpol, PhD
615-936-1512
jennifer.pietenpol@vanderbilt.edu

More Details

NCT ID
NCT00900198
Status
Recruiting
Sponsor
National Cancer Institute (NCI)

Study Contact

Nancy Moore, R.N.
(240) 760-6045
nancy.moore@nih.gov

Detailed Description

Background:

-Patients who are being evaluated and/or treated at the NIH Clinical Center (pediatric and adult) and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.

Objectives:

- To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.

- To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.

Eligibility:

-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and adult patients from participating sites.

Design:

- This is a multicenter tissue procurement protocol with NCI as the coordinating center.

- For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed on adult patients at the NIH Clinical Center for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.

- For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.

- Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.

- This study has three separate consent forms: one for adult patients at the NIH Clinical Center to opt to donate their samples for ongoing research on assay development and studies of molecular pathways; and two for the generation of preclinical models (adult and pediatric). Adult patients at the NIH and participating sites, and also pediatric patients (NIH Clinical Center only), can opt to donate samples to create preclinical models to study tumor biology and genetics, and to develop new therapies for cancer.

- Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.